OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
OKYO Pharma (NASDAQ: OKYO) has been granted U.S. Patent No. 12,053,501 for its OK-101 drug, covering methods for treating symptoms of dry eye disease (DED). The patent, issued on August 6th, specifically addresses the use of OK-101 to treat irritated, burning eyes and blurred vision in DED patients. This development strengthens OKYO's intellectual property position in the multi-billion-dollar DED market.
OKYO Pharma is a clinical-stage biopharmaceutical company focusing on innovative ocular therapies for inflammatory DED and neuropathic corneal pain (NCP). The company's CEO, Dr. Gary S. Jacob, emphasized the importance of this patent in advancing their efforts to address unmet medical needs in ocular pain and inflammation treatment.
OKYO Pharma (NASDAQ: OKYO) ha ottenuto il Brevetto U.S. N. 12,053,501 per il suo farmaco OK-101, che copre i metodi di trattamento dei sintomi della malattia dell'occhio secco (DED). Il brevetto, rilasciato il 6 agosto, affronta specificamente l'uso di OK-101 per trattare occhi irritati, bruciore e visione offuscata nei pazienti affetti da DED. Questo sviluppo rafforza la posizione di proprietà intellettuale di OKYO nel mercato DED da miliardi di dollari.
OKYO Pharma è un'azienda biofarmaceutica in fase clinica che si concentra su terapie oculari innovative per DED infiammatorio e dolore corneale neuropatico (NCP). Il CEO dell'azienda, Dr. Gary S. Jacob, ha sottolineato l'importanza di questo brevetto nel favorire i loro sforzi per affrontare le esigenze mediche insoddisfatte nel trattamento del dolore e dell'infiammazione oculare.
OKYO Pharma (NASDAQ: OKYO) ha recibido la Patente U.S. N. 12,053,501 para su medicamento OK-101, que cubre los métodos para tratar los síntomas de la enfermedad de ojo seco (DED). La patente, emitida el 6 de agosto, aborda específicamente el uso de OK-101 para tratar ojos irritados, ardor y visión borrosa en pacientes con DED. Este desarrollo fortalece la posición de propiedad intelectual de OKYO en el mercado de DED, que vale miles de millones de dólares.
OKYO Pharma es una empresa biofarmacéutica en etapa clínica que se centra en terapias oculares innovadoras para DED inflamatorio y dolor corneal neuropático (NCP). El CEO de la empresa, Dr. Gary S. Jacob, enfatizó la importancia de esta patente en la promoción de sus esfuerzos para abordar las necesidades médicas no satisfechas en el tratamiento del dolor ocular y la inflamación.
OKYO 제약(NASDAQ: OKYO)은 미국 특허 No. 12,053,501을 OK-101 약물에 대해 승인받았으며, 이는 건성안 질환(DED)의 증상을 치료하는 방법을 포함하고 있습니다. 이 특허는 8월 6일에 발급되었으며, DED 환자의 자극받고, 타는 듯한 눈과 흐릿한 시력 치료를 위한 OK-101의 사용에 대해 구체적으로 다루고 있습니다. 이 개발은 OKYO의 수십억 달러 규모의 DED 시장에서의 지적 재산권 위치를 강화합니다.
OKYO 제약은 염증성 DED 및 신경병적 각막 통증(NCP)에 대한 혁신적인 안과 치료에 중점을 둔 임상 단계의 생명공학 회사입니다. 회사의 CEO인 Dr. Gary S. Jacob은 안구 통증 및 염증 치료에서 충족되지 않은 의료 요구를 해결하기 위한 그들의 노력을 발전시키는 데 있어 이 특허의 중요성을 강조했습니다.
OKYO Pharma (NASDAQ: OKYO) a obtenu le brevet américain n° 12,053,501 pour son médicament OK-101, couvrant les méthodes de traitement des symptômes de maladie de l'œil sec (DED). Le brevet, délivré le 6 août, aborde spécifiquement l'utilisation de OK-101 pour traiter les yeux irrités, la sensation de brûlure et la vision floue chez les patients DED. Ce développement renforce la position de propriété intellectuelle d'OKYO sur le marché DED de plusieurs milliards de dollars.
OKYO Pharma est une entreprise biopharmaceutique en phase clinique se concentrant sur des thérapies oculaires innovantes pour le DED inflammatoire et la douleur cornéenne neuropathique (NCP). Le PDG de l'entreprise, Dr. Gary S. Jacob, a souligné l'importance de ce brevet dans l'avancement de leurs efforts pour répondre aux besoins médicaux non satisfaits dans le traitement de la douleur oculaire et de l'inflammation.
OKYO Pharma (NASDAQ: OKYO) hat US-Patent Nr. 12,053,501 für sein Medikament OK-101 erhalten, das Methoden zur Behandlung der Symptome von trockenem Auge (DED) abdeckt. Das Patent wurde am 6. August erteilt und behandelt speziell die Verwendung von OK-101 zur Behandlung von reizenden, brennenden Augen und verschwommenem Sehen bei DED-Patienten. Diese Entwicklung stärkt OKYOs Position im Bereich des geistigen Eigentums auf dem milliardenschweren DED-Markt.
OKYO Pharma ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf innovative Augenheilverfahren für entzündliche DED und neuropathische Hornhautschmerzen (NCP) konzentriert. Der CEO des Unternehmens, Dr. Gary S. Jacob, betonte die Bedeutung dieses Patents für die Fortschritte in ihren Bemühungen, unerfüllte medizinische Bedürfnisse bei der Behandlung von Augenbeschwerden und Entzündungen zu adressieren.
- Granted U.S. Patent No. 12,053,501 for OK-101 drug
- Patent covers treatment of specific dry eye disease symptoms
- Strengthens intellectual property position in multi-billion-dollar market
- Potential for treating neuropathic corneal pain, which lacks FDA-approved therapies
- None.
The grant of U.S. Patent No. 12,053,501 to OKYO Pharma is a significant milestone for the company's intellectual property strategy. This patent specifically covers the use of OK-101 to treat key symptoms of Dry Eye Disease (DED), including irritated, burning eyes and blurred vision. Such protection is important in the competitive pharmaceutical landscape, especially for a
The patent's scope, focusing on symptom treatment, provides OKYO with a strong market position. It potentially allows for broader claims in treating DED symptoms, which could be advantageous in both regulatory approvals and market differentiation. However, investors should note that while patent protection is vital, it doesn't guarantee market success. The company still needs to navigate clinical trials and regulatory approvals successfully.
OKYO Pharma's OK-101 targeting both Dry Eye Disease (DED) and neuropathic corneal pain (NCP) is noteworthy. DED affects millions globally and current treatments often fall short in symptom management. The potential to address irritation, burning and blurred vision could significantly improve patient quality of life.
What's particularly interesting is the inclusion of NCP, an often overlooked condition with no FDA-approved treatments. This dual focus could give OKYO a unique market position. However, it's important to see how OK-101 performs in clinical trials, especially in terms of efficacy and safety profiles compared to existing treatments. The success of OK-101 could potentially reshape treatment paradigms for both DED and NCP, but extensive clinical data will be necessary to support these claims.
OKYO Pharma's patent grant strengthens its position in the lucrative DED market, estimated to reach
However, investors should consider that OKYO is still in the clinical-stage, with significant hurdles ahead. The company's focus on both DED and NCP could be seen as a risk diversification strategy, but it also means splitting resources across two challenging indications. Financial stability and the ability to fund ongoing clinical trials will be crucial. While the patent news is positive, it's important to monitor OKYO's clinical progress and cash position in the coming quarters to fully assess its market potential and investment viability.
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key U.S. Patent No. 12,053,501 which issued on August 6th entitled: “Methods for Treating Symptoms of Dry Eye Disease”. The present disclosure covers issued claims on OK-101’s use to treat irritated, burning eyes and blurred vision in patients suffering from DED, strengthening the Company’s intellectual property position in this field.
“We are delighted with the issuance of this U.S. patent, which underscores the innovative potential of OK-101 to treat DED. This milestone strengthens our intellectual property portfolio and positions OKYO Pharma for continued advancement in addressing significant unmet medical needs,” commented Dr. Gary S. Jacob, Ph.D., CEO of OKYO. “The issuance of this patent further solidifies OKYO Pharma's commitment to advancing novel therapies that aim to improve outcomes for patients suffering from ocular pain and inflammation. The company continues to explore strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates.”
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
What is the new U.S. patent granted to OKYO Pharma for OK-101?
When was the U.S. patent for OKYO Pharma's OK-101 issued?
What conditions does OKYO Pharma (OKYO) focus on treating?
How does the new patent impact OKYO Pharma's position in the market?
